Oluyemi Okupe Sells 11,581 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 11,581 shares of the business’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $24.44, for a total transaction of $283,039.64. Following the completion of the sale, the chief financial officer now directly owns 118,077 shares of the company’s stock, valued at approximately $2,885,801.88. The trade was a 8.93 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Oluyemi Okupe also recently made the following trade(s):

• On Thursday, December 26th, Oluyemi Okupe sold 4,213 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.98, for a total transaction of $126,305.74.
• On Friday, December 20th, Oluyemi Okupe sold 18,959 shares of Hims & Hers Health stock. The stock was sold at an average price of $25.77, for a total transaction of $488,573.43.
• On Monday, November 25th, Oluyemi Okupe sold 101,993 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.62, for a total transaction of $3,021,032.66.
• On Wednesday, November 13th, Oluyemi Okupe sold 142,886 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.93, for a total transaction of $4,276,577.98.

Hims & Hers Health Price Performance

Shares of HIMS stock opened at $27.81 on Thursday. The firm has a market cap of $6.08 billion, a PE ratio of 63.21 and a beta of 1.31. The company has a 50-day moving average of $27.42 and a two-hundred day moving average of $21.72. Hims & Hers Health, Inc. has a 1-year low of $8.14 and a 1-year high of $35.02.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.26. The company had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Hims & Hers Health’s revenue was up 77.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.04) earnings per share. Sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

HIMS has been the topic of several recent research reports. TD Cowen reaffirmed a “buy” rating and set a $28.00 target price on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Needham & Company LLC lifted their target price on shares of Hims & Hers Health from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Monday, January 6th. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. Morgan Stanley initiated coverage on shares of Hims & Hers Health in a research note on Tuesday, December 17th. They set an “overweight” rating and a $42.00 target price on the stock. Finally, Citigroup cut shares of Hims & Hers Health from a “neutral” rating to a “sell” rating and lifted their target price for the stock from $24.00 to $25.00 in a research note on Friday, January 10th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, Hims & Hers Health currently has a consensus rating of “Hold” and an average target price of $25.13.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC boosted its stake in Hims & Hers Health by 113.1% during the second quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock worth $121,936,000 after buying an additional 3,205,108 shares during the period. State Street Corp lifted its position in shares of Hims & Hers Health by 4.7% during the third quarter. State Street Corp now owns 4,626,543 shares of the company’s stock worth $85,221,000 after purchasing an additional 206,078 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Hims & Hers Health by 12.7% during the third quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock worth $79,029,000 after purchasing an additional 482,177 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Hims & Hers Health by 34.5% during the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock worth $63,446,000 after purchasing an additional 883,230 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Hims & Hers Health by 15.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,667,422 shares of the company’s stock worth $30,714,000 after purchasing an additional 218,566 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.